Association between neoadjuvant paclitaxel dose intensity and outcomes in early triple-negative and HER2-positive breast cancer: a real-world data analysis

van Marcke de Lummen, C. J., Pogoda, K., Fenton, H., Vallet, M., Plavc, G., Borges, M., Yousuf, H., Dumas, E., Berlière, M., Ciliberto, G., Duhoux, F., Fano, V., Hall, P., Kolenc Mokotar, K., Lopes Conceicao, L., Pereira, F., Škoporc, A., Thomas, A., Tramonti, G., et al. (2025). Association between neoadjuvant paclitaxel dose intensity and outcomes in early triple-negative and HER2-positive breast cancer: a real-world data analysis. ESMO Real World Data and Digital Oncology, 9(1), 100158. https://doi.org/10.1016/j.esmorw.2025.100158 (Original work published 2025)